Creative Medical Technology Holdings (OTC:CELZ) touted its exosome technology today, reporting that it demonstrated an ability to regenerate healthy brain cells while selectively halting the growth of glioma brain cancer cells in a preclinical model.
The company’s exosomes are vesicles harvested from amniotic stem cell technology, which it licensed from the University of California San Diego in an exclusive deal for the AmnioStem platform.
“Having seen first-hand the devastation and lack of treatment options in glioma patients, I am excited about the prospect of developing a non-toxic biological approach that eventually may provide benefit to this group of patients,” Dr. Santosh Kesari, a neuro-oncologist who previously worked at UCal San Diego, said in prepared remarks.
“The filed patent application contains data showing that while AmnioStem derived exosomes inhibited proliferation of glioma cells, other stem cell types actually increased proliferation of glioma,” chief scientific officer Thomas Ichim added. “We are currently working under the possibility that AmnioStem stem cells may possess unique biological properties that are different from other types of stem cells.”
“From a commercialization perspective, exosomes are simpler to manufacture, store, and deliver as compared to living cells. Additionally, since exosomes are not replicating cells, we anticipate a less complicated FDA regulatory pathway as compared to cellular based products,” president & CEO Timothy Warbington said.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.